N6-Benzyladenosine 是一种腺苷受体激动剂,具有细胞分裂素 (cytokinin) 活性。N6-Benzyladenosine 能将细胞周期阻滞在 G0/G1,并诱导凋亡 (apoptosis)。N6-Benzyladenosine 显示出对弓形虫腺苷激酶和胶质瘤 (glioma) 的抑制作用。
Cas No. | 4294-16-0 |
别名 | Benzyladenosine |
分子式 | C17H19N5O4 |
分子量 | 357.36 |
溶解度 | DMSO : 125 mg/mL (349.79 mM; Need ultrasonic) |
储存条件 | 4°C, protect from light |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | N6-Benzyladenosine is anadenosine receptoragonist, has a cytoactive activity. N6-Benzyladenosine arrests cell cycle at G0/G1 phase and induces cellapoptosis. N6-Benzyladenosine also exerts inhibitory effect onT. gondiiadenosine kinase and glioma[1]-[5]. N6-benzyladenosine suppresses the clonogenic activity and the growth of different neoplastic cells[2]. N6-benzyladenosine results cell morphology alteration and actin cytoskeleton disorganization in T24 cell[2]. N6-benzyladenosine (10 μM; 24 h) is a potent inductor of apoptosis, and belongs to apoptotic systems with distinct caspase-3 and caspase-9 activation[3]. N6-benzyladenosine (0-100 μM; 24 h) induces chromatin condensation, formation of apoptotic bodies, and cleavage of DNA to nucleosomal fragments in a dose-dependent manner[3]. N6-benzyladenosine acts as a selective anti-toxoplasma agent with binding affinity toT. gondiiadenosine kinase (apparent Km=179.8 μM), over human adenosine kinase[4]. N6-benzyladenosine (0-50 μM) shows weak inhibition against adenosine kinase deficient (TgAKS3) strains of Toxoplasma gondii[4]. N6-benzyladenosine (compound 2) (0.3-20 μM) exerts anti-glioma activity by interfering with the mevalonate pathway and inhibiting FPPS (Farnesyl pyrophosphate synthase)[5].
Apoptosis Analysis[3] Cell Line: | HL-60 | Concentration: | 10 μM | Incubation Time: | 24 hours | Result: | Induced cell apoptosis by increasing caspase-3 (DEVDase) as well as caspase-9 (LEHDase) activity, indicating an apoptotic systems with distinct caspase-3/9 activation. |
Apoptosis Analysis[5] Cell Line: | U87MG human glioma cell line. | Concentration: | 0.3, 0.6, 1.2, 2.5, 5, 10, 20 μM | Incubation Time: | 48 hours | Result: | Inhibited glioma growth by interfering with the mevalonate pathway and inhibiting FPPS. |
[1]. Kaminek M, et al. Cytokinin activities of N6-benzyladenosine derivatives hydroxylated on the side-chain phenyl ring. Journal of Plant Growth Regulation. 1987. 6(2):113. [2]. Castiglioni S, et al. N6-isopentenyladenosine and its analogue N6-benzyladenosine induce cell cycle arrest and apoptosis in bladder carcinoma T24 cells. Anticancer Agents Med Chem. 2013 May;13(4):672-8. [3]. Mlejnek P. Caspase inhibition and N6-benzyladenosine-induced apoptosis in HL-60 cells. J Cell Biochem. 2001;83(4):678-89. [4]. Kim YA, et al. Synthesis, biological evaluation and molecular modeling studies of N6-benzyladenosine analogues as potential anti-toxoplasma agents. Biochem Pharmacol. 2007 May 15;73(10):1558-72. [5]. Grimaldi M, et al. NMR for screening and a biochemical assay: Identification of new FPPS inhibitors exerting anticancer activity. Bioorg Chem. 2020 May;98:103449. |